COGT
$35.42
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Intraday
Recent News
What Cogent Biosciences (COGT)'s FDA Acceptance of Bezuclastinib NDA Means For Shareholders
Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Non-Advanced Systemic Mastocytosis and set a Prescription Drug User Fee Act target action date of December 30, 2026, without planning an advisory committee or flagging review issues so far. The pivotal SUMMIT trial results, showing statistically significant symptom improvements, favorable safety, and signs of possible disease modification, underline how central bezuclastinib has...
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.
Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires?
Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best multibagger stocks to invest in according to billionaires. On February 17, Cogent Biosciences released the earnings report for 2025 and entered 2026 with significant regulatory momentum following three positive pivotal trials for its lead candidate, bezuclastinib. The company submitted an NDA for Non-Advanced Systemic Mastocytosis/NonAdvSM in […]
Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches
Cogent Biosciences (NASDAQ:COGT) CEO Andrew Robbins outlined the company’s transition into a pre-commercial stage at an annual healthcare conference, highlighting positive pivotal readouts for its lead candidate bezuclastinib and preparations for potential U.S. launches across multiple indications.
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.